Zoetis Inc. (NYSE:ZTS) Holdings Lifted by TCTC Holdings LLC

TCTC Holdings LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 2.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,760 shares of the company’s stock after acquiring an additional 1,153 shares during the quarter. TCTC Holdings LLC’s holdings in Zoetis were worth $8,159,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of ZTS. Capital Performance Advisors LLP acquired a new stake in Zoetis during the third quarter valued at approximately $33,000. Quarry LP increased its holdings in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares in the last quarter. Fortitude Family Office LLC lifted its position in shares of Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after acquiring an additional 222 shares during the last quarter. LRI Investments LLC bought a new stake in shares of Zoetis during the 1st quarter worth $43,000. Finally, Central Valley Advisors LLC acquired a new position in shares of Zoetis in the 2nd quarter worth $49,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ZTS shares. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research upped their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus lifted their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler boosted their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $221.44.

Zoetis Stock Up 1.5 %

ZTS stock opened at $176.82 on Friday. The company has a 50 day moving average of $188.15 and a two-hundred day moving average of $179.35. The company has a market cap of $79.78 billion, a price-to-earnings ratio of 33.24, a PEG ratio of 2.61 and a beta of 0.90. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a quick ratio of 2.09, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the previous year, the company posted $1.36 earnings per share. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, equities analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is presently 32.52%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.